NOVO B — Novo Nordisk A/S Share News
0.000.00%
Last trade - 00:00- DKK1.19tn
- DKK1.28tn
- DKK309.06bn
Eli Lilly lifts revenue outlook as weight-loss shot demand soars, shares jump (updated)
Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial (updated)
Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial
Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk (updated)
Corrected: UPDATE 2-US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo Nordisk
CVS is trying out pharmacists in chronic health management
Brief: FDA Approves Awiqli First Once-Weekly Insulin For Type 2 Diabetes Mellitus In Pediatric Patients
Dr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
India's Torrent Pharma's profit slips as R&D costs outweigh domestic demand
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
Weight-loss drugs fuel protein boom, but with more consumer scrutiny
Corrected: EXCLUSIVE-Heineken document reveals worries over weight-loss drugs and beer sales
Focus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts